—
C+
C+ The full Closelooknet — membership. Open the C+ overview

DexCom Inc (DXCM) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Company snapshot — DexCom Inc

DXCM in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
DexCom designs and sells continuous glucose monitoring systems for people managing diabetes and metabolic conditions. Its range includes the Dexcom G7 and G6 sensors, the Dexcom ONE+ device meant to replace fingerstick testing, and Stelo, a biosensor for adults with prediabetes or Type 2 diabetes who do not use insulin. It also sells remote-monitoring tools, Dexcom Share and the Follow app, marketed to endocrinologists and diabetes educators. The company is based in San Diego.
Where it sits in the stack
DexCom carries no seat in Rubin or HALO's layered structure; it sits in the Surgical, Med Devices & Animal Health sleeve of our universe, a group of regulated device makers built around long-running product cycles. Within that sleeve it is a supplier of monitoring hardware rather than a customer of any build-out layer.
Who it is priced against
Its peer group covers other device names in that sleeve — Globus Medical, IDEXX Laboratories, Intuitive Surgical, Sonova, Stryker, Sartorius and Insulet — grouped for regulated moats around surgery, sensors, hearing and animal health. The market also compares it with Abbott, which sells a rival glucose-monitoring line.
Why Closelooknet tracks it
DexCom holds a seat in the HALO Growth 100, our growth index outside the megacaps, and in the Nasdaq-100. It carries a Closelooknet score, but only one module has been scored so far, so the overall read is still being built. The diary has not yet logged a quote on the name.
What the diary watches
Whether Stelo, aimed at people who do not use insulin, widens the customer base beyond DexCom's existing diabetes users, and how that shifts its standing against rival sensor makers.

DexCom Inc (DXCM) trades on US exchanges, classified under Healthcare. Constituent of HALO Growth 100.

The Closelooknet company score reads 66/100 composite (momentum 83, quality 80, valuation 37) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelooknet reading that exists for DXCM, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Truist, 2026-09-18

The Street on this name

Analyst actions and the latest print for DXCM from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Truist — target 102 from 93 Target raised to $102 from $93 (+16% to spot) 2026-09-18

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against HALO Growth 100 · Surgical, Med Devices & Animal Health · 7 names with week and year-to-date

Peer group

HALO Growth 100 · Surgical, Med Devices & Animal Health

Robotic surgery, continuous-glucose sensors, cochlear implants, animal-health platforms. Regulated moats, multi-decade compounders.

Compared against DXCM on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-09-25

DayWeekMonth3 months
DXCM−1.0%−3.1%−2.6%+23.5%
Surgical, Med Devices & Animal Health+0.2%+1.4%−3.7%—
HALO Growth 1000.0%+0.2%−7.6%—

Against the index: 3.3 pts behind on the week, 5.0 pts ahead on the month; against its Surgical, Med Devices & Animal Health sleeve 1.1 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Dividends and capital return no distribution in twelve months · buybacks 500 m USD in FY2025

Dividends and capital return

What DXCM pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 500 m USD 1.5% of today's market value
  • Share count −1.7% in FY2025 160 m USD of stock-based compensation in the year
  • Capital returned 500 m USD · 46% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

How it trades on rate days beta 0.34 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How DXCM has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.34 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), DexCom Inc moved 0.34% on average · correlation 0.08 · higher than 34% of US names
  • Beta, last 3 months −0.12 less rate-sensitive lately than over the year
  • On the 10 worst bond days +0.08% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.30% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sector × region Health care in US: +1.8% week · −1.3% month · +6.9% quarter · +12.0% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25

FAQ · from the current data · as of 2026-09-26

Quick answers

What is DexCom Inc (DXCM)?

DexCom Inc trades as DXCM on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is DXCM in a Closelooknet index?

Yes — DexCom Inc is a constituent of HALO Growth 100, as of 2026-09-26.

What is DexCom Inc's Closelooknet composite score?

66 out of 100, with momentum 83, quality 80 and valuation 37 sub-scores, as of 2026-09-26. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does DXCM trade against its moving averages?

-0.3% at the close: Holding 5.5% off its 52-week high. As of 2026-09-24 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is DXCM doing against its Closelooknet index?

Over the past month DexCom Inc is −2.6% against −7.6% for the HALO Growth 100 — 5.0 points ahead of its index, as of 2026-09-25. Its Surgical, Med Devices & Animal Health sleeve is −3.7% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

What does DexCom Inc do?

DexCom designs and sells continuous glucose monitoring systems for people managing diabetes and metabolic conditions. Its range includes the Dexcom G7 and G6 sensors, the Dexcom ONE+ device meant to replace fingerstick testing, and Stelo, a biosensor for adults with prediabetes or Type 2 diabetes who do not use insulin. It also sells remote-monitoring tools, Dexcom Share and the Follow app, marketed to endocrinologists and diabetes educators. Its peer group covers other device names in that sleeve — Globus Medical, IDEXX Laboratories, Intuitive Surgical, Sonova, Stryker, Sartorius and Insulet — grouped for regulated moats around surgery, sensors, hearing and animal health. The market also compares it with Abbott, which sells a rival glucose-monitoring line.

Where does DexCom Inc sit in the AI build-out?

DexCom carries no seat in Rubin or HALO's layered structure; it sits in the Surgical, Med Devices & Animal Health sleeve of our universe, a group of regulated device makers built around long-running product cycles. Within that sleeve it is a supplier of monitoring hardware rather than a customer of any build-out layer. DexCom holds a seat in the HALO Growth 100, our growth index outside the megacaps, and in the Nasdaq-100. It carries a Closelooknet score, but only one module has been scored so far, so the overall read is still being built. The diary has not yet logged a quote on the name.

Does DexCom Inc pay a dividend?

No cash distribution shows in DexCom Inc’s price series over the last three years. In fiscal 2025 the company bought back 500 m USD of its own shares, 46% of that year’s free cash flow. The share count fell 1.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

How does DexCom Inc trade when bond yields rise?

Over the past year DexCom Inc had a beta of 0.34 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 34% of US names. On the 10 sessions in which long bonds fell most it moved +0.08% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What has Wall Street done on DexCom Inc recently?

The most recent analyst action on DexCom Inc on the Closelooknet wire is a price target by Truist on 2026-09-18 (target 102 from 93). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for DXCM, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.